Xenograft rejection and the innate immune system

Current Opinion in Organ Transplantation

Volumn 12, Issue 2, 2007, Pages 142-147

  Sprangers, Ben ^a,b   Waer, Mark ^a   Billiau, An D ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b RESEARCH FOUNDATION FLANDERS FWO   (Belgium)

Author keywords

Complement system; Innate immune system; Macrophages; Natural killer cells; Toll like receptor; Xenograft rejection

Indexed keywords

4 N ACETYLGLUCOSAMINE; 4 N ACETYLGLUCOSAMINE ANTIBODY; ANTIBODY; B7 ANTIGEN; CD40 ANTIGEN; CD47 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CCR7; FC RECEPTOR; GALACTOSE ALPHA 1,3 GALACTOSE BETA1; GALACTOSE ALPHA 1,3 GALACTOSE BETA1 ANTIBODY; GALACTOSYLGALACTOSE; HLA C ANTIGEN; HLA E ANTIGEN; HLA G ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LECTIN; MYELOID DIFFERENTIATION FACTOR 88; N ACETYLGLUCOSAMINE; SILENT INFORMATION REGULATOR PROTEIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; B LYMPHOCYTE; CELLULAR IMMUNITY; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; INNATE IMMUNITY; MACROPHAGE; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; XENOGRAFT;

EID: 34250680157     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32805dfb6d     Document Type: Review

References (101)

1. Cooper DK, Gollackner B, Sachs DH. Will the pig solve the transplantation backlog? Annu Rev Med 2002; 53:133-147.
2. Cascalho M, Platt JL. Xenotransplantation and other means of organ replacement. Nat Rev Immunol 2001; 1:154-160.
3. Ibrahim Z, Busch J, Awwad M, et al. Selected physiologic compatibilities and incompatibilities between human and porcine organ systems. Xenotransplantation 2006; 13:488-499. Reviews the physiologic incompatibilities possibly hindering pig-to-primate xenotransplantation.
4. Schuurman HJ, Cheng J, Lam T. Pathology of xenograft rejection: a commentary. Xenotransplantation 2003; 10:293-299.
5. Ohdan H, Yang YG, Shimizu A, et al. Mixed chimerism induced without lethal conditioning prevents T cell- and anti-Gal alpha 1,3Gal-mediated graft rejection. J Clin Invest 1999; 104:281-290.
6. Ohdan H, Yang YG, Swenson KG, et al. T cell and B cell tolerance to Galalpha1,3Gal-expressing heart xenografts is achieved in alpha1,3-galactosyltransferase-deficient mice by nonmyeloablative induction of mixed chimerism. Transplantation 2001; 71:1532-1542.
7. Yamada K, Yazawa K, Shimizu A, et al. Marked prolongation of porcine renal xenograft survival in baboons through the use of alpha1,3-galactosyltransferase gene-knockout donors and the cotransplantation of vascularized thymic tissue. Nat Med 2005; 11:32-34.
8. Kuwaki K, Tseng YL, Dor FJ, et al. Heart transplantation in baboons using alpha1,3-galactosyltransferase gene-knockout pigs as donors: initial experience. Nat Med 2005; 11:29-31.
9. Chen G, Qian H, Starzl T, et al. Acute rejection is associated with antibodies to non-Gal antigens in baboons using Gal-knockout pig kidneys. Nat Med 2005; 11:1295-1298.
10. Hoffmann JA, Kafatos FC, Janeway CA, et al. Phylogenetic perspectives in innate immunity. Science 1999; 284:1313-1318.
11. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002; 20:197-216.
12. Parker W, Bruno D, Holzknecht ZE, et al. Characterization and affinity isolation of xenoreactive human natural antibodies. J Immunol 1994; 153:3791-3803.
13. Galili U, Shohet SB, Kobrin E, et al. Man, apes, and Old World monkeys differ from other mammals in the expression of alpha-galactosyl epitopes on nucleated cells. J Biol Chem 1988; 263:17755-17762.
14. Good AH, Cooper DK, Malcolm AJ, et al. Identification of carbohydrate structures that bind human antiporcine antibodies: implications for discordant xenografting in humans. Transplant Proc 1992; 24:559-562.
15. Sandrin MS, Vaughan HA, Dabkowski PL, et al. Antipig IgM antibodies in human serum react predominantly with Gal(alpha1-3)Gal epitopes. Proc Natl Acad Sci U S A 1993; 90:11391-11395.
16. Galili U, Mandrell RE, Hamadeh RM, et al. Interaction between human natural antialpha-galactosyl immunoglobulin G and bacteria of the human flora. Infect Immun 1988; 56:1730-1737.
17. Lin SS, Weidner BC, Byrne GW, et al. The role of antibodies in acute vascular rejection of pig-to-baboon cardiac transplants. J Clin Invest 1998; 101:1745-1756.
18. Sato K, Takigami K, Miyatake T, et al. Suppression of delayed xenograft rejection by specific depletion of elicited antibodies of the IgM isotype. Transplantation 1999; 68:844-854.
19. Lam TT, Hausen B, Boeke-Purkis K, et al. Hyperacute rejection of hDAF-transgenic pig organ xenografts in cynomolgus monkeys: influence of preexisting antipig antibodies and prevention by the alpha GAL glycoconjugate GAS914. Xenotransplantation 2004; 11:517-524.
20. Lin SS, Kooyman DL, Daniels LJ, et al. The role of natural anti-Gal alpha 1-3Gal antibodies in hyperacute rejection of pig-to-baboon cardiac xenotransplants. Transpl Immunol 1997; 5:212-218.
21. Kobayashi T, Taniguchi S, Neethling FA, et al. Delayed xenograft rejection of pig-to-baboon cardiac transplants after cobra venom factor therapy. Transplantation 1997; 64:1255-1261.
22. Lam TT, Hausen B, Hook L, et al. The effect of soluble complement receptor type 1 on acute humoral xenograft rejection in hDAF-transgenic pig-to-primate life-supporting kidney xenografts. Xenotransplantation 2005; 12:20-29.
23. Lai L, Kolber-Simonds D, Park KW, et al. Production of alpha-1,3-galactosyltransferase knockout pigs by nuclear transfer cloning. Science 2002; 295:1089-1092.
24. Phelps CJ, Koike C, Vaught TD, et al. Production of alpha 1,3-galactosyltransferase-deficient pigs. Science 2003; 299:411-414.
25. Kolber-Simonds D, Lai L, Watt SR, et al. Production of alpha-1,3-galactosyltransferase null pigs by means of nuclear transfer with fibroblasts bearing loss of heterozygosity mutations. Proc Natl Acad Sci U S A 2004; 101:7335-7340.
26. Ohdan H, Swenson KG, Kitamura H, et al. Tolerization of Gal alpha 1,3Gal-reactive B cells in presensitized alpha 1,3-galactosyltransferase- deficient mice by nonmyeloablative induction of mixed chimerism. Xenotransplantation 2001; 8:227-238.
27. Byrne GW, McCurry KR, Martin MJ, et al. Transgenic pigs expressing human CD59 and decay-accelerating factor produce an intrinsic barrier to complement-mediated damage. Transplantation 1997; 63:149-155.
28. Niemann H, Verhoeyen E, Wonigeit K, et al. Cytomegalovirus early promoter induced expression of hCD59 in porcine organs provides protection against hyperacute rejection. Transplantation 2001; 72:1898-1906.
29. Chen RH, Naficy S, Logan JS, et al. Hearts from transgenic pigs constructed with CD59/DAF genomic clones demonstrate improved survival in primates. Xenotransplantation 1999; 6:194-200.
30. Cowan PJ, Aminian A, Barlow H, et al. Renal xenografts from triple-transgenic pigs are not hyperacutely rejected but cause coagulopathy in nonimmunosuppressed baboons. Transplantation 2000; 69:2504-2515.
31. Takahagi Y, Fujimura T, Miyagawa S, et al. Production of alpha 1,3-galactosyltransferase gene knockout pigs expressing both human decay-accelerating factor and N-acetylglucosaminyltransferase III. Mol Reprod Dev 2005; 71:331-338.
32. Schuurman HJ, Pino-Chavez G, Phillips MJ, et al. Incidence of hyperacute rejection in pig-to-primate transplantation using organs from hDAF-transgenic donors. Transplantation 2002; 73:1146-1151.
33. Loss M, Vangerow B, Schmidtko J, et al. Acute vascular rejection is associated with systemic complement activation in a pig-to-primate kidney xenograft model. Xenotransplantation 2000; 7:186-196.
34. Vangerow B, Hecker JM, Lorenz R, et al. C1-inhibitor for treatment of acute vascular xenograft rejection in cynomolgus recipients of h-DAF transgenic porcine kidneys. Xenotransplantation 2001; 8:266-272.
35. Davis EA, Pruitt SK, Greene PS, et al. Inhibition of complement, evoked antibody, and cellular response prevents rejection of pig-to-primate cardiac xenografts. Transplantation 1996; 62:1018-1023.
36. Arumugam TV, Magnus T, Woodruff TM, et al. Complement mediators in ischemia-reperfusion injury. Clin Chim Acta 2006; 374:33-45.
37. Buerke M, Murohara T, Lefer AM. Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion. Circulation 1995; 91:393-402.
38. Atkinson C, Song H, Lu B, et al. Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. J Clin Invest 2005; 115:2444-2453.
39. De Vries B, Matthijsen RA, Wolfs TG, et al. Inhibition of complement factor C5 protects against renal ischemia-reperfusion injury: inhibition of late apoptosis and inflammation. Transplantation 2003; 75:375-382.
40. Arumugam TV, Woodruff TM, Stocks SZ, et al. Protective effect of a human C5a receptor antagonist against hepatic ischaemia-reperfusion injury in rats. J Hepatol 2004; 40:934-941.
41. Sansonetti PJ. The innate signaling of dangers and the dangers of innate signaling. Nat Immunol 2006; 7:1237-1242.
42. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004; 5:987-995.
43. Schnare M, Barton GM, Holt AC, et al. Toll-like receptors control activation of adaptive immune responses. Nat Immunol 2001; 2:947-950.
44. Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 2003; 299:1033-1036.
45. Yang Y, Huang CT, Huang X, et al. Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat Immunol 2004; 5:508-515.
46. Pasare C, Medzhitov R. Control of B-cell responses by Toll-like receptors. Nature 2005; 438:364-368.
47. Obhrai J, Goldstein DR. The role of toll-like receptors in solid organ transplantation. Transplantation 2006; 81:497-502.
48. Andrade CF, Waddell TK, Keshavjee S, et al. Innate immunity and organ transplantation: the potential role of toll-like receptors. Am J Transplant 2005; 5:969-975.
49. Zhai Y, Shen XD, O'Connell R, et al. Cutting edge: TLR4 activation mediates liver ischemia/reperfusion inflammatory response via IFN regulatory factor 3-dependent MyD88-independent pathway. J Immunol 2004; 173:7115-7119.
50. Oyama J, Blais C Jr, Liu X, et al. Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice. Circulation 2004; 109:784-789.
51. Goldstein DR, Tesar BM, Akira S, et al. Critical role of the Toll-like receptor signal adaptor protein MyD88 in acute allograft rejection. J Clin Invest 2003; 111:1571-1578.
52. Tesar BM, Zhang J, Li Q, et al. TH1 immune responses to fully MHC mismatched allografts are diminished in the absence of MyD88, a toll-like receptor signal adaptor protein. Am J Transplant 2004; 4:1429-1439.
53. Thornley TB, Brehm MA, Markees TG, et al. TLR agonists abrogate costimulation blockade-induced prolongation of skin allografts. J Immunol 2006; 176:1561-1570. Thornley et al. show that TLR signalling abrogates the effects of costimulation blockade-induced prolongation of skin allograft survival by preventing alloreactive CD8+ T-cell apoptosis.
54. Chen L, Wang T, Zhou P, et al. TLR engagement prevents transplantation tolerance. Am J Transplant 2006; 6:2282-2291. This study shows that the status of TLR signalling at the time of transplantation determines whether transplantation tolerance can be induced. Signalling through a single TLR was sufficient to prevent anti-CD154-mediated long-term cardiac allograft acceptance; conversely, absence of TLR signalling led to successful skin allograft acceptance.
55. Walker WE, Nasr IW, Camirand G, et al. Absence of innate MyD88 signaling promotes inducible allograft acceptance. J Immunol 2006; 177:5307-5316. In concordance with Thornley et al. (J Immunol 2006, 176:1561-1570) and Chen et al. (Am J Transplant 2006, 6:2282-2291), these authors show that absence of TLR signalling facilitates induction of allograft acceptance through impairment of inflammatory dendritic cell responses and subsequent reduction of T-cell activation.
56. Johnson GB, Brunn GJ, Kodaira Y, et al. Receptor-mediated monitoring of tissue well being via detection of soluble heparan sulfate by Toll-like receptor 4. J Immunol 2002; 168:5233-5239.
57. Ohashi K, Burkart V, Flohe S, et al. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol 2000; 164:558-561.
58. Guillot L, Balloy V, McCormack FX, et al. Cutting edge: the immunostimulatory activity of the lung surfactant protein-A involves Toll-like receptor 4. J Immunol 2002; 168:5989-5992.
59. Li M, Carpio DF, Zheng Y, et al. An essential role of the NF-kappa B/Toll-like receptor pathway in induction of inflammatory and tissue-repair gene expression by necrotic cells. J Immunol 2001; 166:7128-7135.
60. Alevy YG, Brennan D, Durriya S, et al. Increased expression of the HDJ-2 heat shock protein in biopsies of human rejected kidney. Transplantation 1996; 61:963-967.
61. Rizzo M, Alevy YG, Sundaresan S, et al. Increased expression of HDJ-2 (heat shock protein 40) and heat shock protein 70 in biopsy specimens of transplanted human lungs. J Heart Lung Transplant 1998; 17:241-249.
62. Trieb K, Dirnhofer S, Krumbock N, et al. Heat shock protein expression in the transplanted human kidney. Transpl Int 2001; 14:281-286.
63. Ducloux D, Deschamps M, Yannaraki M, et al. Relevance of Toll-like receptor-4 polymorphisms in renal transplantation. Kidney Int 2005; 67:2454-2461.
64. Fekete A, Viklicky O, Hubacek JA, et al. Association between heat shock protein 70s and toll-like receptor polymorphisms with long-term renal allograft survival. Transpl Int 2006; 19:190-196. Demonstrates that TLR4 polymorphism influences the occurrence, in renal allograft patients, of acute allograft rejection and posttransplant atherosclerotic events.
65. Palmer SM, Burch LH, Davis RD, et al. The role of innate immunity in acute allograft rejection after lung transplantation. Am J Respir Crit Care Med 2003; 168:628-632.
66. Palmer SM, Burch LH, Trindade AJ, et al. Innate immunity influences longterm outcomes after human lung transplant. Am J Respir Crit Care Med 2005; 171:780-785.
67. Palmer SM, Burch LH, Mir S, et al. Donor polymorphisms in Toll-like receptor-4 influence the development of rejection after renal transplantation. Clin Transplant 2006; 20:30-36. Shows that TLR4 polymorphism also plays a role in lung allograft survival.
68. Schmidt P, Krook H, Goto M, et al. MyD88-dependent toll-like receptor signalling is not a requirement for fetal islet xenograft rejection in mice. Xenotransplantation 2004; 11:347-352.
69. Kitchens WH, Uehara S, Chase CM, et al. The changing role of natural killer cells in solid organ rejection and tolerance. Transplantation 2006; 81:811-817. Reviews the role of natural killer cells in solid organ xenotransplantation and allograft transplantation.
70. Lin Y, Vandeputte M, Waer M. Natural killer cell- and macrophage-mediated rejection of concordant xenografts in the absence of T and B cell responses. J Immunol 1997; 158:5658-5667.
71. Xia G, Ji P, Rutgeerts O, et al. Natural killer cell- and macrophage mediated discordant guinea pig→rat xenograft rejection in the absence of complement, xenoantibody and T cell immunity. Transplantation 2000; 70:86-93.
72. Lin Y, Vandeputte M, Waer M. Contribution of activated macrophages to the process of delayed xenograft rejection. Transplantation 1997; 64:1677-1683.
73. Lin Y, Goebels J, Xia G, et al. Induction of specific transplantation tolerance across xenogeneic barriers in the T-independent immune compartment. Nat Med 1998; 4:173-180.
74. Ji P, Xia G, Sefrioui H, et al. Induction of T-independent xenotolerance in a semi-discordant hamster-to-presensitized, nude rat model. Transplantation 1999; 68:130-136.
75. Schneider MK, Forte P, Seebach JD. Adhesive interactions between human NK cells and porcine endothelial cells. Scand J Immunol 2001; 54:70-75.
76. Xu XC, Goodman J, Sasaki H, et al. Activation of natural killer cells and macrophages by porcine endothelial cells augments specific T-cell xenoresponse. Am J Transplant 2002; 2:314-322.
77. Dawson JR, Vidal AC, Malyguine AM. Natural killer cell-endothelial cell interactions in xenotransplantation. Immunol Res 2000; 22:165-176.
78. Goodman DJ, Von Albertini M, Willson A, et al. Direct activation of porcine endothelial cells by human natural killer cells. Transplantation 1996; 61:763-771.
79. Yin D, Zeng H, Ma L, et al. Cutting edge: NK cells mediate IgG1-dependent hyperacute rejection of xenografts. J Immunol 2004; 172:7235-7238.
80. Rieben R, Seebach JD. Xenograft rejection: IgG1, complement and NK cells team up to activate and destroy the endothelium. Trends Immunol 2005; 26:2-5.
81. Hauzenberger E, Klominek J, Holgersson J. Anti-Gal IgG potentiates natural killer cell migration across porcine endothelium via endothelial cell activation and increased natural killer cell motility triggered by CD16 cross-linking. Eur J Immunol 2004; 34:1154-1163.
82. He Z, Ehrnfelt C, Kumagai-Braesch M, et al. Aberrant expression of alpha-Gal on primary human endothelium does not confer susceptibility to NK cell cytotoxicity or increased NK cell adhesion. Eur J Immunol 2004; 34:1185-1195.
83. Baumann BC, Forte P, Hawley RJ, et al. Lack of galactose-alpha-1,3-galactose expression on porcine endothelial cells prevents complement-induced lysis but not direct xenogeneic NK cytotoxicity. J Immunol 2004; 172:6460-6467.
84. Baumann BC, Schneider MK, Lilienfeld BG, et al. Endothelial cells derived from pigs lacking Gal alpha(1,3)Gal: no reduction of human leukocyte adhesion and natural killer cell cytotoxicity. Transplantation 2005; 79:1067-1072.
85. Fiorante P, Banz Y, Mohacsi PJ, et al. Low molecular weight dextran sulfate prevents complement activation and delays hyperacute rejection in pig-tohuman xenotransplantation models. Xenotransplantation 2001; 8:24-35.
86. Seebach JD, Comrack C, Germana S, et al. HLA-Cw3 expression on porcine endothelial cells protects against xenogeneic cytotoxicity mediated by a subset of human NK cells. J Immunol 1997; 159:3655-3661.
87. Forte P, Matter-Reissmann UB, Strasser M, et al. Porcine aortic endothelial cells transfected with HLA-G are partially protected from xenogeneic human NK cytotoxicity. Hum Immunol 2000; 61:1066-1073.
88. Forte P, Baumann BC, Weiss EH, et al. HLA-E expression on porcine cells: protection from human NK cytotoxicity depends on peptide loading. Am J Transplant 2005; 5:2085-2093.
89. Lilienfeld BG, Garcia-Borges C, Crew MD, et al. Porcine UL16-binding protein 1 expressed on the surface of endothelial cells triggers human NK cytotoxicity through NKG2D. J Immunol 2006; 177:2146-2152. An approach to overcoming the problem of natural killer cell cytotoxicity towards xenogeneic cells.
90. Laumonier T, Mohacsi PJ, Matozan KM, et al. Endothelial cell protection by dextran sulfate: a novel strategy to prevent acute vascular rejection in xenotransplantation. Am J Transplant 2004; 4:181-187.
91. Fox A, Mountford J, Braakhuis A, et al. Innate and adaptive immune responses to nonvascular xenografts: evidence that macrophages are direct effectors of xenograft rejection. J Immunol 2001; 166:2133-2140.
92. Oldenborg PA, Zheleznyak A, Fang YF, et al. Role of CD47 as a marker of self on red blood cells. Science 2000; 288:2051-2054.
93. Oldenborg PA, Gresham HD, Lindberg FP. CD47-signal regulatory protein alpha (SIRPalpha) regulates Fcgamma and complement receptor-mediated phagocytosis. J Exp Med 2001; 193:855-862.
94. Wang H, Verhalen J, Madariaga ML, et al. Attenuation of phagocytosis of xenogeneic cells by manipulating CD47. Blood 2006 [Epub ahead of print]. Study showing that forced expression of CD47 on pig organs can prevent phagocytosis of pig cells by mouse macrophages.
95. Subramanian S, Parthasarathy R, Sen S, et al. Species- and cell type-specific interactions between CD47 and human SIRPalpha. Blood 2006; 107: 2548-2556. Despite the results of Wang et al. (Blood 2006, Epub ahead of print), this study shows that pig CD47 is able to interact with human SIRPα and suggests that in pig-to-primate xenotransplantation, this signalling pathway may not be problematic.
96. Rees MA, Butler AJ, Brons IG, et al. Evidence of macrophage receptors capable of direct recognition of xenogeneic epitopes without opsonization. Xenotransplantation 2005; 12:13-19.
97. Abe M, Cheng J, Qi J, et al. Elimination of porcine hemopoietic cells by macrophages in mice. J Immunol 2002; 168:621-628.
98. Basker M, Alwayn IP, Buhler L, et al. Clearance of mobilized porcine peripheral blood progenitor cells is delayed by depletion of the phagocytic reticuloendothelial system in baboons. Transplantation 2001; 72:1278-1285.
99. Cardozo LA, Rouw DB, Ambrose LR, et al. The neutrophil: the unnoticed threat in xenotransplantation? Transplantation 2004; 78:1721-1728.
100. Sheikh S, Parhar R, Al Mohanna F. Rapid static adhesion of human naive neutrophil to naive xenoendothelium under physiologic flow is independent of Galalpha1,3-Gal structures. J Leukoc Biol 2002; 71: 932-940.
101. Al Mohanna F, Saleh S, Parhar RS, et al. Human neutrophil gene expression profiling following xenogeneic encounter with porcine aortic endothelial cells: the occult role of neutrophils in xenograft rejection revealed. J Leukoc Biol 2005; 78:51-61.